Delma Caiati
Stock Analyst at Guggenheim
(1.27)
# 3,726
Out of 5,088 analysts
9
Total ratings
20%
Success rate
-4.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Delma Caiati
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LBRX LB Pharmaceuticals | Reiterated: Buy | $80 | $39.46 | +102.74% | 3 | Oct 28, 2026 | |
| RAPP Rapport Therapeutics | Reiterated: Buy | $65 → $70 | $24.90 | +181.12% | 2 | Oct 20, 2026 | |
| MPLT MapLight Therapeutics | Initiated Coverage: Hold | n/a | $7.56 | - | 1 | Oct 5, 2026 | |
| NBIX Neurocrine Biosciences | Initiated Coverage: Buy | $207 | $147.23 | +40.60% | 1 | Oct 5, 2026 | |
| OVID Ovid Therapeutics | Initiated Coverage: Buy | $7 | $2.58 | +171.32% | 1 | Oct 5, 2026 | |
| XENE Xenon Pharmaceuticals | Initiated Coverage: Buy | $73 | $37.33 | +95.55% | 1 | Oct 5, 2026 |
LB Pharmaceuticals
Oct 28, 2026
Reiterated: Buy
Price Target: $80
Current: $39.46
Upside: +102.74%
Rapport Therapeutics
Oct 20, 2026
Reiterated: Buy
Price Target: $65 → $70
Current: $24.90
Upside: +181.12%
MapLight Therapeutics
Oct 5, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $7.56
Upside: -
Neurocrine Biosciences
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $207
Current: $147.23
Upside: +40.60%
Ovid Therapeutics
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.58
Upside: +171.32%
Xenon Pharmaceuticals
Oct 5, 2026
Initiated Coverage: Buy
Price Target: $73
Current: $37.33
Upside: +95.55%